NCT06699940View on ClinicalTrials.gov

A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents

CompletedOBSERVATIONAL
Enrollment

7,690

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
MDD
Interventions
DEVICE

Transcranial Magnetic Stimulation

Patients between the age of 12-21 received TMS treatment for MDD disorder.

Trial Locations (1)

19355

Neuronetics, Malvern

Sponsors

Lead Sponsor

Neuronetics
All Listed Sponsors
lead

Neuronetics

OTHER

NCT06699940 - A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents | Biotech Hunter | Biotech Hunter